Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis.


Journal

Disease models & mechanisms
ISSN: 1754-8411
Titre abrégé: Dis Model Mech
Pays: England
ID NLM: 101483332

Informations de publication

Date de publication:
29 04 2020
Historique:
received: 04 10 2019
accepted: 13 02 2020
pubmed: 26 2 2020
medline: 11 6 2021
entrez: 26 2 2020
Statut: epublish

Résumé

Normothermic perfusion provides a means to rescue steatotic liver grafts, including by pharmacological defatting. In this study, we tested the potential of new drug combinations to trigger defatting in three human culture models, primary hepatocytes with induced steatosis, primary hepatocytes isolated from steatotic liver, and precision-cut liver slices (PCLS) of steatotic liver. Forskolin, L-carnitine and a PPARα agonist were all combined with rapamycin, an immunosuppressant that induces autophagy, in a D-FAT cocktail. D-FAT was tested alone or in combination with necrosulfonamide, an inhibitor of mixed lineage kinase domain like pseudokinase involved in necroptosis. Within 24 h, in all three models, D-FAT induced a decrease in triglyceride content by 30%, attributable to an upregulation of genes involved in free fatty acid β-oxidation and autophagy, and a downregulation of those involved in lipogenesis. Defatting was accompanied by a decrease in endoplasmic reticulum stress and in the production of reactive oxygen species. The addition of necrosulfonamide increased the efficacy of defatting by 8%-12% in PCLS, with a trend towards increased autophagy. In conclusion, culture models, notably PCLS, are insightful to design strategies for liver graft rescue. Defatting can be rapidly achieved by combinations of drugs targeting mitochondrial oxidative metabolism, macro-autophagy and lipogenesis.

Identifiants

pubmed: 32094147
pii: dmm.042663
doi: 10.1242/dmm.042663
pmc: PMC7197711
pii:
doi:

Substances chimiques

Acrylamides 0
Fatty Acids 0
N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide 0
Sulfonamides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare no competing or financial interests.

Références

Hepatol Int. 2019 Jan;13(1):51-57
pubmed: 30515676
Lab Invest. 2016 Jun;96(6):672-9
pubmed: 26950484
PLoS One. 2018 Jul 25;13(7):e0201419
pubmed: 30044872
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
J Hepatol. 2013 May;58(5):993-9
pubmed: 23339953
World J Gastroenterol. 2014 Sep 28;20(36):12956-80
pubmed: 25278691
FASEB J. 2007 May;21(7):1433-44
pubmed: 17283223
Hepatol Res. 2016 Aug;46(9):933-43
pubmed: 26666995
Curr Opin Organ Transplant. 2017 Dec;22(6):555-562
pubmed: 28922300
Biochim Biophys Acta. 2013 Feb;1831(2):387-97
pubmed: 22951416
Transplantation. 1992 Jul;54(1):167-70
pubmed: 1631928
Liver Transpl. 2019 Jul;25(7):1007-1022
pubmed: 30821045
Chem Biol Interact. 2007 Jan 30;165(2):106-16
pubmed: 17188672
Mol Metab. 2019 May;23:14-23
pubmed: 30837196
Nat Commun. 2016 Jun 21;7:11869
pubmed: 27323669
Am J Clin Nutr. 2002 Oct;76(4):750-7
pubmed: 12324287
Biochem Biophys Res Commun. 2016 Jan 22;469(4):1104-10
pubmed: 26687947
J Biol Chem. 1993 Jun 15;268(17):12713-8
pubmed: 8509406
Diabetes. 2010 Apr;59(4):775-81
pubmed: 20068142
Nat Protoc. 2010 Sep;5(9):1540-51
pubmed: 20725069
J Hepatol. 2013 Dec;59(6):1307-14
pubmed: 23872604
Metabolism. 2007 Nov;56(11):1500-7
pubmed: 17950100
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Am J Transplant. 2012 Sep;12(9):2477-86
pubmed: 22594953
Metab Eng. 2009 Jul-Sep;11(4-5):274-83
pubmed: 19508897
Hepatology. 2018 Aug;68(2):496-514
pubmed: 29457836
Cell Biol Int. 2018 Sep;42(10):1282-1291
pubmed: 29908010
PLoS One. 2016 Jul 20;11(7):e0159729
pubmed: 27438262
J Hepatol. 2017 Sep 21;:
pubmed: 28870676
Curr Opin Lipidol. 2012 Jun;23(3):226-34
pubmed: 22449814
Exp Gerontol. 2016 Oct;83:130-8
pubmed: 27498120
Hum Mol Genet. 2019 Jan 1;28(1):143-154
pubmed: 30256948

Auteurs

Lynda Aoudjehane (L)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France lynda.aoudjehane@inserm.fr.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.

Jérémie Gautheron (J)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.

Wilfried Le Goff (W)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.

Claire Goumard (C)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.
Department of Hepatobiliary and Liver Transplantation Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France.

Julia Gilaizeau (J)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.

Chan Sonavine Nget (CS)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.

Eric Savier (E)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.
Department of Hepatobiliary and Liver Transplantation Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France.

Muhammad Atif (M)

Centre d'immunologie et maladies infectieuses, Sorbonne Université, INSERM, U1135, Paris 75013, France.

Philippe Lesnik (P)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.

Romain Morichon (R)

Production et Analyse des données en Sciences de la vie et en Santé (PASS), Sorbonne Université, INSERM, UMS 37, Paris 75013, France.

Yves Chrétien (Y)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.

Yvon Calmus (Y)

Department of Medical Liver Transplantation, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France.

Olivier Scatton (O)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.
Department of Hepatobiliary and Liver Transplantation Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France.

Chantal Housset (C)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.
Department of Hepatology, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75012, France.

Filomena Conti (F)

Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, INSERM, Paris 75012, France.
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, INSERM, Paris 75013, France.
Department of Medical Liver Transplantation, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH